Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenesis; Anti angiogenic therapy; Endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CADHERIN; CD133 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 8; METHOTREXATE; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; BREAST CANCER; CLINICAL MEDICINE; CLINICAL TRIAL; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; LOW DRUG DOSE; MICROVASCULATURE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; TUMOR VASCULARIZATION;

EID: 71749083382     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70272-3     Document Type: Article

References (15)

1. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
2. Bertolini F., Mancuso P., Shaked Y., and Kerbel R.S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12 (2007) 806-812
3. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
4. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6 (2006) 835-845
5. Eckelman W.C., Reba R.C., and Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 13 (2008) 748-759
6. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., and St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11 (2007) 539-554
7. Yoder M.C., Mead L.E., Prater D., Krier T.R., Mroueh K.N., Li F., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109 (2007) 1801-1809
8. Case J., Mead L.E., Bessler W.K., Prater D., White H.A., Saadatzadeh M.R., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35 (2007) 1109-1118
9. Mancuso P., Antoniotti P., Quarna J., Calleri A., Rabascio C., Tacchetti C., et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15 (2009) 267-273
10. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2 (2002) 826-835
11. Mancuso P., Colleoni M., Calleri A., Orlando L., Maisonneuve P., Pruneri G., et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108 (2006) 452-459
12. F ̈ urstenberger G., von Moos R., Lucas R., Thürlimann B., Senn H.J., Hamacher J., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94 (2006) 524-531
13. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., et al. Bloodbased biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
14. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26 (2008) 4899-4905
15. Torrisi R., Bagnardi V., Cardillo A., Bertolini F., Scarano E., Orlando L., et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER-and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99 (2008) 1564-1571